NCT00504790View on ClinicalTrials.gov

Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

June 25, 2007

Primary Completion Date

May 7, 2012

Study Completion Date

May 8, 2012

Conditions

Cancer

Interventions

DRUG

GSK923295

anti-mitotic compound

Trial Locations (3)

48201

GSK Investigational Site, Detroit

91010

GSK Investigational Site, Duarte

53792-5666

GSK Investigational Site, Madison

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY